




+



Sheet	1	of	3
-------	---	----	---

Application Number	09/868,120
Filing Date	June 14, 2001
First Named Inventor	David Thomas Dudley, et al.
Group Art Unit	1617
Examiner Name	San Ming R Hui
Attorney Docket Number	5968-01-SMH

#8
HKD
03/19/03

[illegible][illegible]

US\$N 09/868, 120
5968-SMH
EXPRESS MAIL NO. EF22071596511S
FILED: June 14, 2001

Examiner
Signature

Carly

Date	
Considered	

3/19/03

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/868,120
				Filing Date	June 14, 2001
				First Named Inventor	David Thomas Dudley, et al.
				Group Art Unit	1617
				Examiner Name	San Ming R Hui
				Attorney Docket Number	5968-01-SMH
Sheet	2	of	3		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM	/	DARIO R. ALESSI, et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Bio. Chem., 11/17/1995, pp 27489-27494, Vol. 270, No. 46	
	/	ALISON M. BADGER, et al., "SB 203580 Inhibits p38 Mitogen-Activated Protein Kinase, Nitric Oxide Production, and Inducible Nitric Oxide Synthase in Bovine Cartilage-Derived Chondrocytes", J. Immun., 1998, pp 467-473, Vol. 161	
	/	MICHELE A. BROGLEY, et al., "Basic Calcium Phosphate Crystal Induction of Collagenase 1 and Stromelysin Expression Is Dependent on a p42/44 Mitogen-Activated Protein Kinase Signal Transduction Pathway", J. Cell. Physiol., 1999, pp 215-224, Vol. 180	
	/	JOHN V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorg. Med. Chem. Letters, 1998, pp 2839-2844, Vol. 8	
	/	GARY S. FIRESTEIN, et al., "Signal Transduction and Transcription Factors in Rheumatic Disease", Arthritis & Rheumatism, 4/4/1999, pp 609-621, Vol. 42, No. 4	
	/	YU GENG, et al., "Selective Activation of the Mitogen-activated Protein Kinase Subgroups c-Jun NH2 Terminal Kinase and p38 by IL-1 and TNF in Human Articular Chondrocytes", J. Clin. Invest., 11/1996, pp 2425-2430, Vol. 98, No. 10	
	/	THOMAS D. GEPPERT, et al., "Lipopolysaccharide Signals Activation of Tumor Necrosis Factor Biosynthesis Through the Ras/Raf-1/MEK/MAPK Pathway, Mol. Med., 11/1994, pp 93-103, Vol. 1, No. 1	
	/	JAMES R. HENRY, et al., "Potent Inhibitors of the MAP Kinase p38", Bioorg. Med. Chem. Letters, 1998, pp 3335-3340, Vol. 8	
	/	DANIEL HWANG, et al., "Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide", Biochem. Pharm., 1997, pp 87-96, Vol. 54	
	/	JEFFREY R. JACKSON, et al., "Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models", J. Pharm. Experm. Thera., 1998, pp 687-692, Vol. 284	
SM	/	EDWARD KORZUS, et al., "The Mitogen-activated Protein Kinase and JAK-STAT Signaling Pathways are Required for an Oncostatin M-responsive Element-mediated Activation of Matrix Metalloproteinase 1 Gene Expression", J. Biol. Chem., 1/10/1997, pp 1188-1196, Vol. 272, No. 2	

Examiner Signature		Date Considered	3/19/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/868,120
Filing Date	June 14, 2001
First Named Inventor	David Thomas Dudley, et al.
Group Art Unit	1617
Examiner Name	San Ming R Hui
Attorney Docket Number	5968-01-SMH

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH	/	WEN QING LI, et al., "Oncostatin M Up-Regulates Tissue Inhibitor of Metalloproteinases-3 Gene Expression in Articular Chondrocytes Via De Novo Transcription, Protein Synthesis, and Tyrosine Kinase- and Mitogen-Activated Protein Kinase-Dependent Mechanisms" J. Immu., 1998, pp. 5000-5007, Vol. 161	
	/	LISA J. MCCAWLEY, et al., "Sustained Activation of the Mitogen-activated Protein Kinase Pathway," The J. Biol. Chem., 1999, pp 4347-4353, Vol. 274, No. 7	
	/	KEIJI MIYAZAWA, et al., "Regulation of Interleukin-1B-induced Interleukin-6 Gene Expression in Human Fibroblast-like Synoviocytes by p38 Mitogen-activated Protein Kinase," J. Biol. Chem., 9/1998, pp 24832-24838, Vol. 273, No. 38	
	/	JUKKA WESTERMARCK, et al., "Enhancement of Fibroblast Collagenase-1 (MMP-1) Gene Expression by Tumor Promoter Okadaic Acid Is Mediated by Stress-Activated Protein Kinases Jun N-terminal Kinase and p38," Matrix Biol., 1998, pp 547-557, Vol. 17	
SH	/	MARY E. ZEIGLER, et al., "Role of ERK and JNK Pathways in Regulating Cell Motility and Matrix Metalloproteinase 9 Production in Growth Factor-Stimulated Human Epidermal Keratinocytes," J. Cell. Physio., 1999, pp 271-284, Vol. 180	

Examiner
Signature

Date
Considered

3/19/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.